Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | DAGLA | Q9Y4D2 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | ABHD11 | Q8NFV4 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2073337 | 0.94 | L3MBTL1 (0.48) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL3607904 | 0.94 | L3MBTL1 (0.48) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL3348343 | 0.94 | L3MBTL1 (0.48) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL28070422 | 0.86 | KMT2A (0.53) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL22287170 | 0.85 | — | — | |
| SCHEMBL22371739 | 0.85 | NPC1 (0.40) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL7762330 | 0.85 | L3MBTL1 (0.53) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL20819833 | 0.85 | NPC1 (0.40) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL14645821 | 0.85 | NPC1 (0.40) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL12606498 | 0.84 | KMT2A (0.51) | NPC1RAB9AKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3867248-B1 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-12-10 | — | — | EP | claimed |
| US-20250115587-A1 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2025-04-10 | — | — | US | claimed |
| US-20210300906-A1 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2021-09-30 | — | — | US | claimed |
| CN-113272297-A | Pyrazole derivatives as H4 antagonist compounds | 赫普泰雅治疗有限公司 | 2021-08-17 | — | — | CN | claimed |
| WO-2020079457-A1 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-04-23 | — | — | WO | claimed |
| US-8426441-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2013-04-23 | — | — | US | claimed |
| EP-2009992-B1 | IL-8 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2012-06-27 | — | — | EP | claimed |
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-07-23 | — | — | US | claimed |
| EP-1314728-A1 | Pyridyl and pyrimidinyl imines as intermediates for imidazole derivatives | SMITHKLINE BEECHAM CORPORATION (US) | 2003-05-28 | — | — | EP | claimed |
| EP-0831830-B1 | IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2003-03-05 | — | — | EP | claimed |
| US-6372741-B1 | ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2002-04-16 | — | — | US | claimed |
| EP-1005343-A1 | USE OF CSAID?TM COMPOUNDS AS INHIBITORS OF ANGIOGENESIS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-06-07 | — | — | EP | claimed |
| EP-1005343-A4 | USE OF CSAID?TM COMPOUNDS AS INHIBITORS OF ANGIOGENESIS | SMITHKLINE BEECHAM CORP (US) | 2000-06-07 | — | — | EP | claimed |
| EP-0889888-A1 | NOVEL TREATMENT FOR CNS INJURIES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-13 | — | — | EP | claimed |
| EP-0831830-A4 | IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 1998-12-02 | — | — | EP | claimed |
| EP-0831830-A1 | IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1997035856-A1 | NOVEL TREATMENT FOR CNS INJURIES | SMITHKLINE BEECHAM CORPORATION (US) | 1997-10-02 | — | — | WO | claimed |
| WO-1997032583-A1 | USE OF CSAIDTM COMPOUNDS AS INHIBITORS OF ANGIOGENESIS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-09-12 | — | — | WO | claimed |
| US-5658903-A | Imidazole compounds, compositions and use | SMITHKLINE BEECHAM CORPORATION (US) | 1997-08-19 | — | — | US | claimed |
| WO-1996040143-A1 | IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-12-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | BTK, SYK, LYN | NPC1 4614/4885RAB9A 1472/4885KMT2A 1922/4885 |
| US-20210300906-A1 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | HRH4, HRH3, HDAC3 | NPC1 432/4885RAB9A 2119/4885KMT2A 1080/4885 |
| US-20250115587-A1 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | HRH4, HRH3, HDAC3 | NPC1 432/4885RAB9A 2119/4885KMT2A 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.